Regorafenib, nivolumab, chemo combo found safe and effective for various cancers, heading to phase 3 trial (18% better than other options)

Medical Xpress / The Lancet Oncology ^ | Sept. 7, 2023 | Justin Jackson / Samuel L Cytryn et al / Kazuhiro Shiraishi et al

[ConservativeMind]

Researchers have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.

The findings suggest that regorafenib and nivolumab with chemotherapy is safe and demonstrates some anti-tumor activity in patients with advanced oesophagogastric cancer. Based on these results, a randomized phase 3 clinical trial of the combination is planned.

In previous studies, each of the drugs has demonstrated potential effectiveness against oesophagogastric adenocarcinoma. Combining these agents was expected to enhance the overall efficacy of the treatment, potentially providing better results.

Despite the initial benefits of immunotherapy (like nivolumab) and chemotherapy in treating oesophagogastric cancer, many patients eventually develop therapeutic resistance. The addition of regorafenib, which can modulate the tumor microenvironment and enhance immune responses was a strategic approach to potentially overcome or delay the development of resistance.

Nivolumab is an immune checkpoint inhibitor that can activate the patient's own immune system to target cancer cells. Regorafenib, in addition to its direct anti-tumor effects, can enhance the function of natural killer cells and CD8+ T cells while inhibiting immunosuppressive factors produced by the tumor.

Oesophagogastric cancer is the second-leading cause of cancer-related deaths, resulting in approximately 1.3 million fatalities annually. Many patients are diagnosed with a metastatic form of disease, which is challenging to treat effectively as it spreads to various regions in the body.

At the 6-month assessment, 25 of the 35 evaluable patients (71%) were progression-free, meeting the primary endpoint, an 18% improvement over historically derived control of 53%.

Follow up assessments conducted approximately 18 months later revealed the most common adverse event was fatigue (92% of patients). Serious adverse events occurred in 26% of patients, which were acute kidney injury (8%), hepatotoxicity (5%), sepsis (5%), dry skin, pruritus, or rash (3%), nausea (3%), and gastric perforation (3%). There were no treatment-related deaths.

[ConservativeMind]

Each therapy is currently available.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[Bobalu]

Thanks again for posting these articles... they are interesting :-)

[Bob434]

yes they are- always good to keep up on what’s new in this field- as it’s such a devastating one, cancer i mean-

[sauropod]

.